Axolabs

Axolabs company information, Employees & Contact Information

Explore related pages

Related company profiles:

Axolabs specialises in a new class of drugs whose active ingredients are chemically derived from DNA or RNA. They are called oligonucleotide or nucleic acid therapeutics. We use our many years of expertise to help our clients make them a success. Some of these drugs have already been approved and are being used successfully against diseases that were previously untreatable in some cases. New drugs from this class are added every year. Axolabs is part of the LGC Group. Its business unit for nucleic acid therapeutics is combined under the brand name Axolabs. Axolabs operates companies in the following locations: Axolabs, Kulmbach, Germany Axolab Kulmbach GmbH, is the world’s leading custom research organization in the field of nucleic acid therapeutics with a wide range of services. Axolabs Berlin, Berlin, Germany Axolabs Berlin is currently establishing a new site in Berlin for GMP manufacturing of nucleic acid therapeutics. The site will be dedicated to medium to large scale and early to late phase clinical GMP manufacturing of nucleic acid therapeutics. The state-of-the-art facility will deliver integrated analytical and manufacturing solutions. The operational start date is scheduled for 2025. Axolabs Petaluma, Petaluma, California, USA Axolabs operates a cGMP production facility in Petaluma for oligonucleotide compounds for technical, toxicological and preclinical to late-stage clinical trials. Services: bioinformatics, oligonucleotide synthesis, analytics and in vitro / in vivo analysis.

Company Details

Employees
181
Founded
-
Address
Fritz-Hornschuch Straße 9, Kulmbach,bayern 95326,germany
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Kulmbach, Bayern
Looking for a particular Axolabs employee's phone or email?

Axolabs Questions

News

Asahi Kasei Bioprocess and Axolabs Announce Strategic Partnership to Accelerate Oligonucleotide Therapeutics Development - Business Wire

Asahi Kasei Bioprocess and Axolabs Announce Strategic Partnership to Accelerate Oligonucleotide Therapeutics Development Business Wire

Asahi Kasei and Axolabs team to co-market oligonucleotide therapeutics - BioProcess International

Asahi Kasei and Axolabs team to co-market oligonucleotide therapeutics BioProcess International

Asahi Kasei and Axolabs Partner on Oligonucleotide Therapeutics - Genetic Engineering and Biotechnology News

Asahi Kasei and Axolabs Partner on Oligonucleotide Therapeutics Genetic Engineering and Biotechnology News

LGC to develop new Berlin site to expand nucleic acid therapeutics capacity - SelectScience

LGC to develop new Berlin site to expand nucleic acid therapeutics capacity SelectScience

LGC Snaps Up Axolabs, Adding to TNA Capabilities - Genetic Engineering and Biotechnology News

LGC Snaps Up Axolabs, Adding to TNA Capabilities Genetic Engineering and Biotechnology News

Top Axolabs Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant